超声深度学习影像组学可早期预测乳腺癌新辅助化疗反应:一项前瞻性研究
该前瞻性研究纳入168例经临床病理确诊的乳腺癌患者,在NAC前、第2周期后和第4周期后行超声检查,构建DLR-2和DLR-4模型及DLRP阶梯预测流程。验证队列中DLR-2预测第2周期后反应的AUC为0.812,DLR-4预测第4周期后反应的AUC为0.937、特异度90.5%,DLRP成功识别21例无反应患者中的19例。
要点
- 超声DLR模型可在NAC早期(第2、4周期后)预测病理反应,辅助早期调整治疗策略。
- DLR-4验证队列AUC 0.937、特异度90.5%,DLR-2的NPV为83.3%。
- DLRP阶梯流程识别21例无反应者中的19例,提示可早期干预。
核心结论
- 基于超声图像的DLRP策略可有效预测乳腺癌患者NAC早期反应,为个体化治疗提供工具。
研究设计与样本
- 前瞻性研究,纳入168例经临床病理确诊的乳腺癌患者,2016年3月至2020年12月。
- 所有患者完成NAC,并在NAC前、第2周期后、第4周期后三个时间点行超声检查。
- 开发DLR-2和DLR-4两个模型分别预测第2和第4周期后的反应,并提出DLRP用于不同时间点的阶梯预测。
诊断标准与关键数值
- 验证队列中DLR-2预测第2周期后反应的AUC为0.812(95%CI 0.770-0.851),NPV为83.3%(95%CI 76.5-89.6)。
- 验证队列中DLR-4预测第4周期后反应的AUC为0.937(95%CI 0.913-0.955),特异度为90.5%(95%CI 86.3-94.2)。
- DLRP成功识别21例无反应患者中的19例。
临床应用与阅片要点
- 可在NAC第2、4周期后利用超声DLR模型评估反应,辅助早期识别可能无反应者。
- DLRP阶梯预测流程可整合不同时间点信息,为调整治疗策略提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Breast cancer (BC) is the most common cancer in women worldwide, and neoadjuvant chemotherapy (NAC) is considered the standard of treatment for most patients with BC. However, response rates to NAC vary among patients, which leads to delays in appropriate treatment and affects the prognosis for patients who ineffectively respond to NAC. This study aimed to investigate the feasibility of deep learning radiomics (DLR) in the prediction of NAC response at an early stage.
METHODS: In total, 168 patients with clinicopathologically confirmed BC were enrolled in this prospective study, from March 2016 to December 2020. All patients completed NAC treatment and underwent ultrasonography (US) at three time points (before NAC, after the second course, and after the fourth course). We developed two DLR models, DLR-2 and DLR-4, for predicting responses after the second and fourth courses of NAC. Furthermore, a novel deep learning radiomics pipeline (DLRP) was proposed for stepwise prediction of response at different time points of NAC administration.
RESULTS: In the validation cohort, DLR-2 achieved an AUC of 0.812 (95% CI: 0.770-0.851) with an NPV of 83.3% (95% CI: 76.5-89.6). DLR-4 achieved an AUC of 0.937 (95% CI: 0.913-0.955) with a specificity of 90.5% (95% CI: 86.3-94.2). Moreover, 19 of 21 non-response patients were successfully identified by DLRP, suggesting that they could benefit from treatment strategy adjustment at an early stage of NAC.
CONCLUSIONS: The proposed DLRP strategy holds promise for effectively predicting NAC response at its early stage for BC patients.
KEY POINTS: • We proposed two novel deep learning radiomics (DLR) models to predict response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients based on US images at different NAC time points. • Combining two DLR models, a deep learning radiomics pipeline (DLRP) was proposed for stepwise prediction of response to NAC. • The DLRP may provide BC patients and physicians with an effective and feasible tool to predict response to NAC at an early stage and to determine further personalized treatment options.
引用
- Gu J, Tong T, He C, et al. Deep learning radiomics of ultrasonography can predict response to neoadjuvant chemotherapy in breast cancer at an early stage of treatment: a prospective study. Eur Radiol. 2021. PMID: 34654965. doi:10.1007/s00330-021-08293-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。